Press Releases

- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial

- Long-term efficacy results in older patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial

NEW YORK, May 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals,... (continue reading...)

CALGARY, AB, May 14, 2024 /PRNewswire/ - Strathcona Resources Ltd. ("Strathcona" or the "Company") (TSX: SCR) today reported its first quarter 2024 financial and operational results.

Highlights

• Production of 185,122 boe/d (71% oil and condensate, 77% liquids)(1)
• Operating Earnings of $209.0 million ($0.98 / share)(2)
• Free Cash Flow of $157.9 million... (continue reading...)

TRANSACTION WILL INCREASE CET1 CAPITAL RATIO TO 10.8% ON A PROFORMA BASIS AND FURTHER BOLSTER LIQUIDITY

LOAN-TO-DEPOSIT RATIO IMPROVES TO 104%

HICKSVILLE, N.Y., May 14, 2024 /PRNewswire/ -- New York Community Bancorp, Inc. (NYSE: NYCB) (the "Company"), the parent company of Flagstar Bank, N.A. (the "Bank") announced today that it has agreed to sell approximately $5 billion in mortgage warehouse loans to JPMorgan Chase Bank, N.A. ("JPMC").

... (continue reading...)

CLEVELAND, May 14, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a multicenter double-blind randomized, placebo-controlled trial of individuals experiencing moderate-to-severe postoperative pain following knee replacement and treatment with the SPRINT PNS System. The study, published in the journal Neuromodulation, highlights the results from the prospective trial evaluating the impact of 60-day peripheral nerve stimulation (PNS) used for... (continue reading...)

BRISBANE, Australia, May 15, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ: NVX, ASX: NVX), a leading battery materials and technology company, and PowerCo SE (“PowerCo”), a Volkswagen Group-owned battery cell company, have announced the signing of a non-exclusive Testing and Development Agreement (“TDA”). The work to be conducted under the TDA will include NOVONIX developing, testing, and analyzing synthetic graphite anode materials tailored to meet... (continue reading...)